^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4433 Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
Published date:
11/03/2022
Excerpt:
9/35 pts (26%) achieved CR/CRi with BM-uMRD after 1 year of DUV+VEN and electively discontinued therapy in remission, including 4 pts with del(17p)….In the 16 CLL pts with TP53-aberrancy, the best ORR was 50% (CR 44%, PR 6%)….A time-limited, all oral regimen DUV + VEN is active in R/R CLL and RS, including in high-risk pts post-BTKi.
DOI:
https://doi.org/10.1182/blood-2022-169986
Trial ID:
